Generic Name and Formulations:
Memantine HCl extended-release, donepezil HCl; 7mg/10mg, 14mg/10mg, 21mg/10mg, 28mg/10mg; caps.
Indications for NAMZARIC:
Moderate-to-severe dementia of the Alzheimer's type in patients stabilized on 10mg of donepezil HCl once daily.
Swallow whole or may open caps and sprinkle on applesauce, then consume entire contents; do not divide doses. Patients stabilized on donepezil HCl 10mg: initially 7mg/10mg once daily in the PM; increase at minimum weekly intervals in 7mg increments of memantine HCl to max maintenance dose of 28mg/10mg once daily; severe renal impairment (CrCl 5–29mL/min): initially 7mg/10mg once daily in the PM; increase to maintenance dose of 14mg/10mg once daily after one week. Patients stabilized on both components: 28mg/10mg once daily in the PM. Start the day after last dose of memantine HCl and donepezil HCl given separately. Severe renal impairment (CrCl 5–29mL/min): 14mg/10mg once daily.
Cardiac conduction abnormalities. Peptic ulcer. Monitor for GI bleeding. GU obstruction. Alkalinized urine (eg, renal tubular acidosis, severe UTI) increases memantine levels. Seizures. Asthma or COPD. Severe hepatic impairment. Pregnancy. Nursing mothers.
NMDA receptor antagonist + acetylcholinesterase inhibitor.
Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan). Memantine plasma levels may be increased by urinary alkalinizers. Donepezil potentiated by CYP3A4 (eg, ketoconazole) and CYP2D6 (eg, quinidine) inhibitors. CYP3A4 inducers (eg, phenytoin, carbamazepine, dexamethasone, rifampin, phenobarbital) may increase the rate of elimination of donepezil. Antagonizes anticholinergics. Additive effects with succinylcholine-type muscle relaxants (during anesthesia), other cholinesterase inhibitors, cholinergic agonists (eg, bethanechol). Concomitant NSAIDs may increase risk of GI bleed.
Headache, diarrhea, dizziness, anorexia, vomiting, nausea, ecchymosis.
Caps 7mg/10mg, 21mg/10mg—30; 14mg/10mg, 28mg/10mg—30, 90
Neurology Advisor Articles
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- Loss of Function Variants in LRRK1 and LRRK2 Not Linked to Parkinson Disease
- Smoking Promotes Disease Progression in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- ZTlido Patch for Post-Shingles Pain Launching Soon
- Managing Complications of Intrathecal Baclofen Therapy
- Deep Brain Stimulation Reduces Tremor Symptoms in Parkinson Disease
- FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
- Prevalence of Autoimmune Encephalitis in Herpes Simplex Encephalitis Explored